Quarterly report pursuant to Section 13 or 15(d)

Condensed Combined and Consolidated Statements of Operations (Unaudited)

v3.19.3.a.u2
Condensed Combined and Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:        
Research and development (includes share-based compensation expense) [1] $ 4,953 $ 7,683 $ 33,759 $ 17,763
General and administrative (includes share-based compensation expense) [2] 6,088 1,201 11,836 1,729
Total operating expenses 11,041 8,884 45,595 19,492
Interest expense 376   625  
Other (income)/expense, net (221) (43) (539) 63
Loss before provision for income taxes (11,196) (8,841) (45,681) (19,555)
Income tax expense 100 8 156 12
Net loss $ (11,296) $ (8,849) $ (45,837) $ (19,567)
Net loss per common share - basic and diluted [3] $ (0.28) $ (0.24) $ (1.16) $ (1.16)
Weighted-average common shares outstanding – basic and diluted [3] 41,035,055 36,735,341 39,408,236 16,815,727
[1] Includes $0 and $152 of costs allocated from Roivant Sciences Ltd. for the three and nine months ended December 31, 2019, respectively, and $475 and $3,209 of costs allocated from Roivant Sciences Ltd. for the three and nine months ended December 31, 2018, respectively.
[2] Includes $487 and $1,001 of costs allocated from Roivant Sciences Ltd. for the three and nine months ended December 31, 2019, respectively, and $637 and $930 of costs allocated from Roivant Sciences Ltd. for the three and nine months ended December 31, 2018, respectively.
[3] Retroactively restated for the reverse recapitalization as described in Note 1.